

Attorney Docket No.: MDSP-P02-180

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

---

1. (Currently Amended) A method for inhibiting reduction of bone density in a mammalian patient having a pathological condition in which bone density is decreased, comprising administering to said patient an effective amount of an anti-IL-11 antibody, which inhibiting in the patient the formation of a tertiary complex of Interleukin-11 (IL-11), Interleukin-11 receptor (IL-11R), and glycoprotein 130 (gp130), to increase osteoblast-mediated bone formation and to decrease osteoclast-mediated bone resorption, thereby decreasing the rate in loss of bone density in said mammalian patient.
2. (Canceled)
3. (Currently Amended) The method of claim 2 1, wherein the pathological condition is postmenopausal bone loss.
- 4-13. (Canceled)
14. (Currently Amended) The method of claim 2 1, wherein ~~the substance~~ said anti-IL-11 antibody is a small molecule no more than 30 kd in molecular weight.
- 15-42. (Canceled)
43. (New) The method of claim 1, wherein said anti-IL-11 antibody is a whole antibody of isotype IgG, IgA, IgM, IgD, or IgE, or a functional fragment thereof which retain an antigen binding site.
44. (New) The method of claim 1, wherein said anti-IL-11 antibody is a chimeric, hybrid, or genetically engineered antibody, or a functional fragment thereof which retain an antigen binding site.
45. (New) The method of claim 1, wherein said IL-11 antibody is a proteolytic and/or recombinant fragment, including Fab, F(ab')<sub>2</sub>, Fab', Fv, and single chain antibody (scFv) containing a V[L] and/or V[H] domain joined by a peptide linker.
46. (New) The method of claim 1, wherein said IL-11 antibody comprises several scFv covalently or non-covalently linked to form an antibody having two or more binding sites.

Attorney Docket No.: MDSP-P02-180

- E1
47. (New) The method of claim 1, wherein said IL-11 antibody is a polyclonal antibody.
  48. (New) The method of claim 1, wherein said IL-11 antibody is a purified preparation of antibodies or recombinant antibodies.
  49. (New) The method of claim 1, wherein said IL-11 antibody is a monoclonal antibody.
  50. (New) The method of claim 49, wherein said monoclonal antibody is a humanized monoclonal antibody.
-